Helsinn Healthcare SA is a Swiss-based world leader in cancer care that focuses on building quality cancer care together with partners who share its values.
Helsinn is a family-run pharmaceutical company that delivers leading cancer supportive care, and is built on strong values of respect, integrity and quality. We develop, manufacture and supply a range of innovative solutions in cancer supportive care that impact everyday patients' quality of life.
After 40 successful years of providing cancer supportive care, Helsinn recognized a new unmet need in the cancer care field - the need for scientific evidence to endorse the integration of non-pharmaceutical supportive care products.
Our Integrative Care team was created to focus fully on the development and delivery of high-quality, high-purity, evidence-based products for people with cancer and survivors of the disease.
Through the highest standards of quality assurance, we are committed to improving quality of life for people before, during and after cancer.
Our products can also be used by people who are undergoing cancer treatment.
They have been proved to be safe and have no interactions with radio and chemo therapy. These products can be categorized as complementary food supplements and medical devices.
Address the quest for a better quality of life by meeting patients' and their caregivers' needs in their fight against cancer and endurance to cancer treatments' side-effects, with high standard, evidence based, safe and reliable non–pharmaceutical-qualified products endorsed by their healthcare providers.
Helsinn Integrative Care is set to become the company of reference for healthcare providers in the cancer supportive care area, for value added solutions addressing cancer patients' needs with evidence based non pharmaceutical products, for High Corporate Values, High Operating Standards and High Product Quality.
Helsinn Integrative Care delivers to the market products that differ from similar products because of the clinical data that supports their use specifically in the cancer setting.